It's Hard to Make Money When FDA Approvals Are Priced In

ARIAD Pharmaceuticals got its leukemia drug ponatinib approved by the Food and Drug Administration today. Shares are down 14% as I write this .

Why? It's tempting to blame it on the new brand name Iclusig. My stomach turns just saying it. I realize a lot of the powerful sounding names -- Novartis' Afinitor and Dendreon's Provenge, for instance -- have been taken, but the brand names seem to be getting worse lately.

Alas, I doubt investors care about the name that much. Instead, my guess is this is simply a sell-the-news event. The approval was no surprise. The data was solid. Even an early approval wasn't all that surprising, especially after announcing it wouldn't have to wait for a companion diagnostic to be approved. The company used the FDA's fast track rolling submission to get some of the data in front of FDA reviewers early. And the FDA has been making quick decisions about oncology drugs recently. Approvals for Medivation's Xtandi and Bayer and Onyx Pharmaceuticals' Stivarga both came in a month or more before the PDUFA date.


With the binary event out of the way, investors have to wait to see how well Iclusig will sell. The drug will be used after Otsuka and Bristol-Myers Squibb's Sprycel, or Novartis' Tasigna, or by patients with a mutation that doesn't allow them to take those drugs.

Investors could be fretting about the boxed warning on the label, pointing out the potential for blood clots and liver toxicity , but I don't see it as a major issue. The drug is patients' last resort; side effects are a secondary concern when death is inevitable.

At a market cap of $3.3 billion, much of the early sales of the drug are already built into ARIAD's share price. ARIAD's CEO Harvey Berger told Bloomberg that it was targeting annual sales of $600 million to $800 million in the 2017 to 2018 time frame. Assuming a multiple of five times sales, that would value the company at $3 billion to $4 billion.

If ARIAD is going to grow from here, it'll have to do it with its other drugs. Ridaforolimus, which is partnered with Merck , might not be dead yet, despite being turned down by the FDA as a treatment for sarcoma. And ARIA has two other drugs in clinical development.

Success of any of those programs should have the usual effect of sending shares upwards.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article It's Hard to Make Money When FDA Approvals Are Priced In originally appeared on Fool.com.

Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum